/
We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hem…
The business is unprofitable at the operating level (-1315.38% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 266.7% YoY with margins expanding 3472.3pp.
Negative free cash flow of -$140M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$9M
▲ +266.7% YoY
Net Income (TTM)
-$124M
▼ -1.8% YoY
Op. Margin
-1408.73%
▲ +3472.3pp YoY
ROIC
-44.22%
▼ -2.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$125M
▼ -21.9% YoY
Op. Cash Flow (TTM)
-$122M
▼ -22.1% YoY
Net Debt
-$36M
Net Cash Position
Cash & Equiv.
$128M
5Y CAGR: +56.9%
Continue Research